Tranexamic acid sitixamic 500mg5 ml solution for injection IV is a hemostatic formulation designed to reduce excessive bleeding by inhibiting fibrinolysis. This standardized concentrate supports clinicians in managing surgical and traumatic blood loss with predictable pharmacokinetics.
Healthcare teams rely on precise dosing protocols and compatibility data to ensure safe delivery in acute care environments. The following sections outline key therapeutic, operational, and safety considerations for this specific product.
| Active ingredient | Concentration | Route | Typical adult dose |
|---|---|---|---|
| Tranexamic acid (as sitixamic) | 500 mg in 5 ml | Intravenous injection | 500 mg to 1 g, adjusted for bleed severity |
| Onset of action | 10–20 minutes | Loading strategy | Bolus followed by infusion if needed |
| Metabolism | Hepatic | Renal clearance | Up to 80% unchanged in urine |
| Storage condition | 2–8°C | Shelf life | 24 months from manufacture |
Pharmacology and Mechanism of Action
Tranexamic acid sitixamic competitively blocks lysine binding sites on plasminogen, thereby reducing plasmin formation and preserving fibrin clots. This mechanism curtails hyperfibrinolysis without interfering with initial coagulation pathways.
Clinicians appreciate its predictable dose–response relationship, which allows for protocol-driven administration in trauma, obstetric, and surgical settings. Steady-state concentrations are reached rapidly when the recommended infusion rate is maintained, supporting consistent hemostatic effect.
Indications and Clinical Uses
Regulatory authorities approve this formulation for reducing bleeding in procedures with high blood loss risk, including major orthopedic surgery and postpartum hemorrhage management. Off-label use may be considered in critical care after multidisciplinary review.
Guideline integration across surgical pathways helps standardize timing and dosing, minimizing variability in control versus intervention groups. Early administration within the first hour of bleeding correlates with improved hemoglobin preservation and reduced transfusion requirements.
Dosing, Administration, and Monitoring
Loading doses are typically followed by maintenance infusions, with adjustments for renal impairment and body weight. Involving pharmacy services early supports accurate dilution, compatibility checks, and adherence to institutional protocols.
Monitoring parameters include hemodynamic stability, laboratory hemostatic markers, and urine output when renal function is at risk. Clinicians should reassess bleeding control regularly to balance antifibrinolytic benefit against potential thrombotic risk.
Safety, Contraindications, and Precautions
Known hypersensitivity to tranexamic acid or excipients, a history of venous thromboembolism, and active clotting disorders represent key contraindications. Caution is warranted in patients with subclinical thrombotic risk, cerebrovascular disease, or concomitant prothrombotic therapies.
Adverse events may include nausea, headache, and infusion-related reactions; rare reports of visual disturbances emphasize the need for prompt reporting and dose interruption if severe. Regular renal function assessment is advised, especially in elderly patients or those with chronic kidney disease.
Operational and Quality Considerations
- Verify patient identity, indication, and allergy status before preparation
- Prepare solutions in a controlled environment using aseptic technique
- Confirm compatibility and stability of the final mixture
- Document batch number, expiry, and administration details accurately
- Monitor for therapeutic response and adverse events throughout infusion
Clinical Leadership and Protocol Optimization
Structured protocols that integrate tranexamic acid sitixamic 500mg5 ml solution for injection IV with multidisciplinary review support standardized care across departments. Continuous quality review of dosing patterns, outcomes, and adverse events informs iterative improvements to institutional guidelines.
FAQ
Reader questions
How should this solution be diluted before intravenous administration?
Use only specified infusion diluents and follow the manufacturer’s instructions to prepare a stable concentration for controlled IV delivery over the recommended time window.
Can it be used in patients with mild renal impairment?
Dose adjustment is generally recommended when creatinine clearance falls below specified thresholds; consult local guidelines and monitor renal function during therapy.
What should be done if bleeding persists after the initial dose?
Reassess hemodynamics, coagulation status, and surgical hemostasis; consider repeating or continuous infusion under specialist supervision while evaluating for alternate causes of ongoing blood loss.
Is this product compatible with common intravenous fluids and medications?
Verify compatibility with the selected carrier fluid and co-administered drugs through pharmacy checks to prevent physical or chemical interactions that could compromise safety or efficacy.